An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.
OBJECTIVE
To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.


RESULTS
This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P < 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin ( pound1531 vs. pound1769; difference pound238; 95% CI: pound73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group ( pound1769 vs. pound2072; difference pound303; 95% CI: pound138-468, P < 0.001). Overall, rosuvastatin was found to cost pound1840 (95% CI: pound562-6028) per major CV event avoided.


CONCLUSIONS
This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
Lorgelly
Paula K
PK
Section of Public Health and Health Policy, Faculty of Medicine, University of Glasgow, Glasgow G12 8RZ, UK.
Briggs
Andrew H
AH
Wedel
Hans
H
Dunselman
Peter
P
Hjalmarson
Ake
A
Kjekshus
John
J
Waagstein
Finn
F
Wikstrand
John
J
Jánosi
András
A
van Veldhuisen
Dirk J
DJ
Barrios
Vivencio
V
Fonseca
Cândida
C
McMurray
John J V
JJ
D000368:Aged; D002315:Cardiopulmonary Bypass / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D005464:Fluorobenzenes / Q000191:economics* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics*; D016027:Heart Transplantation / Q000706:statistics & numerical data; D017052:Hospital Mortality; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011743:Pyrimidines / Q000191:economics* / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium